Free Stock & ETF Comparisons

Compare GSK and AstraZeneca by oncology pipeline growth, respiratory franchise strength, RSV vaccine competition, dividend yield, and which British pharma ADR offers better returns.

Compare Roche and Johnson & Johnson by cancer diagnostics vs medical device mix, oncology biosimilar exposure, dividend yield, pipeline depth, and which healthcare ADR is the better buy.

Compare IDEXX Laboratories and Zoetis by veterinary diagnostics vs animal pharmaceutical revenue, pet humanisation tailwind, international expansion, and premium growth stock valuation.

Compare Medtronic and Boston Scientific by pipeline innovation velocity, structural heart market share, robotic-assisted surgery entry, international revenue mix, and valuation.

Compare CVS Health and Walgreens Boots Alliance by pharmacy benefit management revenue, health services pivot, store closure strategy, dividend sustainability, and turnaround timeline.

Compare AbbVie and Johnson & Johnson by Skyrizi/Rinvoq growth vs diversified MedTech earnings, Humira transition risk, dividend growth history, and payout sustainability.

Compare Thermo Fisher Scientific and Danaher by lab instrument and reagent revenue, bioproduction recovery, M&A track record, free cash flow compounding, and valuation.

Compare Danaher and West Pharmaceutical Services by lab tools vs drug containment revenue, biopharma customer mix, GLP-1 drug packaging tailwind, and long-term compounder quality.

Compare Illumina and Pacific Biosciences by DNA sequencing market share, short-read vs long-read accuracy, instrument installed base, and genomics precision medicine revenue.

Compare Becton Dickinson and Abbott Laboratories by medical device vs diagnostics revenue mix, diabetes CGM competition, biosurgery market, dividend growth, and long-term value.

Compare Hologic and Illumina by molecular diagnostics revenue durability, cervical cancer screening adoption, genomic sequencing market penetration, and post-COVID base effect.

Compare Charles River Laboratories and IQVIA by preclinical contract research revenue, clinical data analytics ARR, biopharma customer mix, and post-biotech funding recovery timing.

Compare Masimo and Intuitive Surgical by patient monitoring sensor revenue, da Vinci procedure volume, capital equipment cycle, and consumer health pivots vs pure medical device revenue.

Compare Arrowhead Pharmaceuticals and Moderna by RNA drug platform approach, cardiometabolic pipeline progress, clinical trial risk, cash runway, and emerging biologic revenue.

Compare Vertex Pharmaceuticals and CRISPR Therapeutics by Casgevy gene editing revenue launch, CF franchise durability, pipeline beyond approved therapies, and biotech valuation.

Compare Global Medical REIT and Alexandria Real Estate Equities by medical office vs life science campus tenant quality, occupancy, lease term length, dividend coverage, and risk profile.

Compare Moderna and Recursion Pharmaceuticals by mRNA oncology pipeline vs AI-driven drug discovery platform, clinical-stage pipeline diversity, cash runway, and which next-generation biotech platform creates more long-term value.

Compare Regeneron and Vertex Pharmaceuticals by Eylea/Dupixent commercial durability, Trikafta CFTR sales, R&D pipeline depth, and which large-cap biotech has more durable long-term earnings power.

Compare Biogen and Gilead Sciences by Leqembi Alzheimer's commercial ramp, Biktarvy HIV franchise durability, oncology cell therapy pipeline, and which mid-to-large biotech offers better risk-adjusted upside.

Compare Alnylam and Ionis Pharmaceuticals by siRNA platform royalty stack, antisense oligonucleotide licensing revenue, Inclisiran commercial growth, and which nucleic acid medicine platform is better positioned.

Compare CRISPR Therapeutics and Editas Medicine by exa-cel sickle cell commercial launch, CRISPR delivery modality, patent position, cash runway, and which gene editing stock is the better speculation.

Compare Intellia Therapeutics and CRISPR Therapeutics by in-vivo liver delivery vs ex-vivo stem cell editing, transthyretin amyloidosis program, cash position, and clinical milestone catalysts.

Compare Exact Sciences and GoodRx by Cologuard screening revenue growth, GoodRx pharmacy network monetisation, gross margin trajectory, and which healthcare tech platform is the better recovery story.

Compare Halozyme Therapeutics and ACADIA Pharmaceuticals by ENHANZE royalty stream growth, Daybue Rett syndrome commercial launch, pipeline risk, and which specialty pharma has more predictable revenue.

Compare Gilead Sciences and Merck by Biktarvy HIV franchise durability, Keytruda immuno-oncology patent cliff risk, HIV prevention lenacapavir launch, HPV vaccine market share, and which large pharma is better valued.

Compare Amwell and Hims & Hers by telehealth visit volume, DTC subscription growth, GLP-1 weight loss medication revenue, insurance coverage partnerships, and which health tech stock is better positioned.

Compare One Medical (Amazon Health) and Teladoc Health by membership primary care hybrid model, BetterHelp mental health growth, ARPU, and which digital-physical healthcare model wins enterprise employer health budgets.

Compare STERIS and Danaher by hospital sterile reprocessing service revenue, biotech instrument replacement cycle, consumable annuity revenue, and which medtech/life science platform compounder is a better buy post-biotech slowdown.

Compare Intuitive Surgical and NovaCure by da Vinci surgical system installed base, Optune TTFields clinical expansion, recurring instrument revenue, gross margin, and which medical device company captures a unique clinical moat.

Compare iRhythm Technologies and Inspire Medical Systems by Zio patch wearable cardiac monitoring ARR, hypoglossal nerve stimulation implant growth, insurance coverage expansion, and which medtech niche device company scales faster.

Compare Omnicell and Veeva Systems by hospital pharmacy automation ARR, Veeva CRM replacement revenue, subscription model transition, and which healthcare software company has a more defensible enterprise position.

Compare Perrigo and Amgen by consumer OTC healthcare products (Aleve, Compeed), biosimilar revenue ramp, obesity drug pipeline (Amgen), and which pharma stock offers better risk-adjusted returns.

Compare Jazz Pharmaceuticals and Axsome Therapeutics by Xywav narcolepsy franchise, AXS-05 MDD/Alzheimer's agitation launch, pipeline risk, and which CNS specialty pharma has more durable revenue.

Compare DexCom and Tandem Diabetes Care by continuous glucose monitor market share, closed-loop insulin delivery integration, OTC CGM opportunity, Abbott competition, and which diabetes device company has a clearer growth path.

Compare Insulet (Omnipod) and Tandem Diabetes Care by tubeless vs tubed insulin pump design preference, Omnipod 5 AID market penetration, international expansion pace, and which insulin pump company has more runway.

Compare NovaCure and Beam Therapeutics by TTFields revenue in glioblastoma/NSCLC, base editing precision gene therapy pipeline, clinical data readouts, and which cancer-focused biotech/medtech is the better speculative bet.

Compare Community Health Systems and Tenet Healthcare by rural community hospital revenue cycle, ambulatory surgery center (USPI) expansion, debt load, payer mix, and which hospital operator has the more credible deleveraging path.

Compare Oscar Health and Alignment Healthcare by ACA individual marketplace growth, Medicare Advantage risk model, medical loss ratio trend, per-member-per-month margin, and which tech-enabled health insurance company scales to profitability first.

Compare iRhythm Technologies and Agios Pharmaceuticals by Zio wearable cardiac monitor revenue, Tibsovo/Pyrukynd rare disease franchise, cash position, and which small/mid-cap healthcare company is on a better profitability path.

Compare Agiliti and Halozyme Therapeutics by medical equipment lifecycle service revenue, ENHANZE subcutaneous delivery royalties, recurring revenue predictability, and which healthcare services company is the more defensive investment.

Compare Veeva Systems and Medidata (Dassault Systèmes) by CRM replacement revenue in pharma, clinical data management ARR, Vault R&D suite adoption, and which life sciences software platform has the deeper regulatory moat.

Compare Teladoc Health and Hims & Hers by BetterHelp mental health retention, GLP-1 weight loss subscription revenue, medical provider network depth, ARPU, and which consumer health tech platform reaches sustainable profitability first.

Compare Envista Holdings and Danaher by dental implant/aligners market share, bioprocess equipment demand (post-COVID), consumable revenue mix, and which Danaher spin-off/peer offers more upside as life science end markets recover.

Compare Hologic and Becton Dickinson by molecular diagnostics revenue sustainability post-COVID, surgical robot (Hologic Fluent) launch, BD Alaris infusion pump recall recovery, and which medtech delivers more consistent organic growth.

Compare ResMed and Philips by CPAP market share gains from Philips recall, AirSense connected device subscription ARR, Philips Sleep & Respiratory Care recovery timeline, and which sleep apnea device company is the better investment.

Compare Thermo Fisher Scientific and Agilent Technologies by bioproduction instrument and consumable revenue recovery, mass spectrometry market leadership, pharmaceutical and biotech customer capex cycle, and which instrument giant compounds better.

Compare Illumina and Pacific Biosciences by short-read sequencing market share, long-read sequencing clinical and research adoption, oncology liquid biopsy opportunity, and which genomics sequencing company leads the next decade.

Compare Natera and GRAIL by multi-cancer early detection test market development, Signatera MRD monitoring revenue, Galleri commercial launch progress, insurance coverage milestones, and which liquid biopsy company reaches profitability first.